Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2019

14.11.2019 | short review

Second-line therapy in metastatic renal cell cancer—how do we treat after immuno-oncology drugs?

verfasst von: MD Ursula Vogl

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

The treatment landscape of metastatic renal cell cancer (mRCC) is rapidly evolving. To date in 2019 twelve drugs are licensed for this indication, two more drugs are awaited to be introduced into our portfolio of treatment options by the end of the year. First-line treatment has robust clinical trial data and is clearly stated by the consensus guidelines. It consists either of a tyrosine kinase inhibitor (TKI) monotherapy for favorable risk patients—defined by the Heng or IMDC (International mRCC Database Consortium) score—or the immuno-oncology (IO) combination of ipilimumab and nivolumab (Ipi/Nivo) for intermediate- and poor-risk patients who are eligible for this treatment. To date we have a clearly positive phase III trial of a TKI-IO combination that was superior to standard of care with sunitinib in untreated metastatic patients independent of the risk group. Pembrolizumab and axitinib will be most likely introduced to the treatment landscape by the end of the year. Despite all these very enthusiastic treatment options in first line, subsequent treatment recommendations are missing due to the lack of data. Only retrospective data can be used as a tool to make the right choice after the use of an IO drug in first line.
Literatur
1.
Zurück zum Zitat Albiges L, Powles T, Staehler M, et al. Updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. 2019;76(2):151–6. CrossRef Albiges L, Powles T, Staehler M, et al. Updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. 2019;76(2):151–6. CrossRef
2.
Zurück zum Zitat Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810. CrossRef Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810. CrossRef
3.
Zurück zum Zitat Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(5):706–20. CrossRef Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(5):706–20. CrossRef
4.
Zurück zum Zitat Jonasch E. NCCN guidelines updates: management of metastatic kidney cancer. J Natl Compr Canc Netw. 2019;17(5.5):587–9. PubMed Jonasch E. NCCN guidelines updates: management of metastatic kidney cancer. J Natl Compr Canc Netw. 2019;17(5.5):587–9. PubMed
5.
Zurück zum Zitat Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. CrossRef Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. CrossRef
6.
Zurück zum Zitat Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–23. CrossRef Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–23. CrossRef
7.
Zurück zum Zitat Motzer RJ, Hutson TE, Ren M, et al. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol. 2016;17(1):e4–5. CrossRef Motzer RJ, Hutson TE, Ren M, et al. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol. 2016;17(1):e4–5. CrossRef
8.
Zurück zum Zitat Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–62. CrossRef Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–62. CrossRef
9.
Zurück zum Zitat Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56. CrossRef Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56. CrossRef
10.
Zurück zum Zitat Barata PC, De Liano AG, Mendiratta P, et al. The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. Br J Cancer. 2018;119(2):160–3. CrossRef Barata PC, De Liano AG, Mendiratta P, et al. The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. Br J Cancer. 2018;119(2):160–3. CrossRef
11.
Zurück zum Zitat Shah AY, Kotecha RR, Lemke EA, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. 2019;114:67–75. CrossRef Shah AY, Kotecha RR, Lemke EA, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. 2019;114:67–75. CrossRef
12.
Zurück zum Zitat Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27. CrossRef Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27. CrossRef
13.
Zurück zum Zitat Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35(6):591–7. CrossRef Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35(6):591–7. CrossRef
14.
Zurück zum Zitat Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31(30):3791–9. CrossRef Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31(30):3791–9. CrossRef
15.
Zurück zum Zitat Auvray M, Auclin E, Barthelemy P, et al. Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ [Eur J Cancer 108 (February 2019) 33–40]. Eur J Cancer. 2019;119:200–1. CrossRef Auvray M, Auclin E, Barthelemy P, et al. Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ [Eur J Cancer 108 (February 2019) 33–40]. Eur J Cancer. 2019;119:200–1. CrossRef
16.
Zurück zum Zitat Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–15. CrossRef Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–15. CrossRef
17.
Zurück zum Zitat Schmidinger M, Pichler R, Loidl W, et al. Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study. Clin Genitourin Cancer. 2019;17(5):e957–e67. CrossRef Schmidinger M, Pichler R, Loidl W, et al. Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study. Clin Genitourin Cancer. 2019;17(5):e957–e67. CrossRef
Metadaten
Titel
Second-line therapy in metastatic renal cell cancer—how do we treat after immuno-oncology drugs?
verfasst von
MD Ursula Vogl
Publikationsdatum
14.11.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-00545-4